Arcadia Biosciences, Inc. (RKDA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RKDA Revenue Growth
Revenue Breakdown (FY 2025)
RKDA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RKDA Revenue Analysis (2014–2025)
As of May 8, 2026, Arcadia Biosciences, Inc. (RKDA) generated trailing twelve-month (TTM) revenue of $4.9 million, reflecting significant decline in growth of -25.9% year-over-year. The most recent quarter (Q4 2025) recorded $901,000 in revenue, down 30.8% sequentially.
Looking at the longer-term picture, RKDA's 5-year compound annual growth rate (CAGR) stands at -9.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $8.0 million in 2020.
Revenue diversification analysis shows RKDA's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Basic Materials sector peers including PGEN (+59.2% YoY), OFIX (+2.6% YoY), and SEED (-22.1% YoY), RKDA has underperformed the peer group in terms of revenue growth. Compare RKDA vs PGEN →
RKDA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RKDACurrent | $5M | -25.9% | -9.6% | -205.7% | |
 PGEN | $4M | +59.2% | -34.3% | -3440.2% | |
 OFIX | $822M | +2.6% | +15.1% | -8.3% | |
 SEED | $90M | -22.1% | +11.4% | -58.9% | |
 CTVA | $17.4B | +6.3% | +4.1% | 15.1% | |
 FMC | $3.5B | -16.6% | -5.7% | -54.4% |
RKDA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.9M | -3.7% | $1.8M | 36.2% | $-9,995,000 | -205.7% |
| 2024 | $5.0M | +13.3% | $2.1M | 41.3% | $-3,648,000 | -72.3% |
| 2023 | $4.5M | -40.0% | $2.3M | 51.2% | $-6,102,000 | -137.0% |
| 2022 | $7.4M | +9.4% | $1.3M | 17.8% | $-14,007,000 | -188.8% |
| 2021 | $6.8M | -15.6% | $-1,928,000 | -28.4% | $-35,526,000 | -524.0% |
| 2020 | $8.0M | +587.3% | $2.8M | 35.3% | $-12,778,000 | -159.0% |
| 2019 | $1.2M | -20.2% | $284K | 24.3% | $-19,381,000 | -1657.9% |
| 2018 | $1.5M | -63.6% | $803K | 54.8% | $-16,870,000 | -1152.3% |
| 2017 | $4.0M | +26.3% | $3.7M | 93.0% | $-14,315,000 | -355.6% |
| 2016 | $3.2M | -41.1% | $2.3M | 71.9% | $-18,620,000 | -584.1% |
See RKDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RKDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RKDA vs LIN
Side-by-side business, growth, and profitability comparison vs Linde plc.
Start ComparisonRKDA — Frequently Asked Questions
Quick answers to the most common questions about buying RKDA stock.
Is RKDA's revenue growth accelerating or slowing?
RKDA revenue declined -25.9% year-over-year, contrasting with the 5-year CAGR of -9.6%. TTM revenue fell to $5M. This reverses the prior growth trend.
What is RKDA's long-term revenue growth rate?
Arcadia Biosciences, Inc.'s 5-year revenue CAGR of -9.6% reflects the variable expansion pattern. Current YoY growth of -25.9% is below this long-term average.
How is RKDA's revenue distributed by segment?
RKDA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.